A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
43actual
Sites
1
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-14 | actual | When the study began enrolling |
| Primary completion | 2025-03-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-04 | actual | The whole study's end, after follow-up |
| First posted | 2024-06-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Drug: NNC0487-0111 A
- Drug: NNC0487-0111 C
- Drug: Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)
- Drug: Acetaminophen - 500 mg/15 ml
Primary outcomes
what the primary-completion date above is the date OFThe area under the ethinylestradiol plasma concentration time curve at steady state
measured Day 8 and Day 193
The area under the levonorgestrel plasma concentration time curve at steady state
measured Day 8 and Day 193
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed